Given that PGI increases cell migration and invasion via AMFR, the use of an anti-AMFR antibody has been shown to reduce the migratory and invasive capabilities in ccRCC (Lucarelli et al., 2015). This evidence concerns the gene AMFR and nonpapillary renal cell carcinoma.